DiaSafe™ technology for non-invasive DFU risk assessment and early intervention*The DFU treatment market is estimated to be approximately$10 billion globally1Rosh Pina, Israel--(Newsfile Corp. - November...
PressureSafe(TM) clinical results presented to global nursing leaders; the Company engages with U.S. investment community and national media in parallel visibility pushRosh Pina, Israel--(Newsfile Corp....
Rosh Pina, Israel--(Newsfile Corp. - September 16, 2025) - IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"), a developer of non-invasive artificial intelligence (AI)-powered spectrographic technology...
PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdownTechnology addresses longstanding disparities in skin...
DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers for assessment of diabetic foot ulcers The most common cause of amputation, diabetic foot...
/PRNewswire/ -- "IR-MED" or the "Company" (OTCQB:IRME), an innovative medical device company that develops non-invasive, real-time detection devices that...
Rosh Pinna, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- (“IR-MED or the “Company”) (OTCQB:IRME), an innovative development stage medical device company...
IR-Med (“ IR-MED or the “ Company ”) ( OTCQB:IRME) , an innovative development-stage medical device company utilizing Infra-Red light spectroscopy (IR) and Artificial Intelligence (AI) technologies...
IR-Med (“ IR-MED or the “ Company ”) ( OTCQB:IRME) , an innovative development stage medical device company that utilizes Infra-Red light spectroscopy (IR) combined with Artificial Intelligence...